Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from selected healthy newborn umbilical cord tissue through in vitro separation, expansion, harvesting, and freezing [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]

Group 1 - The company will participate in the "2025 Tianjin Listed Companies Investor Online Collective Reception Day and Half-Year Performance Briefing" to enhance interaction with investors [1][2] - The event will be held online on September 11, 2025, from 15:00 to 17:00, allowing investors to join via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [1][2] - Key company representatives attending the event include Vice Chairman and General Manager Wang Hongqi, independent directors Hou Xinyi and Luo Mingsheng, and CFO Chen Yiqing [2] Group 2 - The company will address investor concerns regarding its 2025 half-year performance, corporate governance, development strategy, and operational status during the event [2] - The company encourages widespread participation from investors in this interactive session [2]

Group 1 - The company Zhongyuan Qihe announced its participation in the 2025 Tianjin-listed companies investor online reception day and semi-annual performance briefing [2] - The event is scheduled for September 11, 2025 [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-036 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP，参与本次互动交流。活动时间为 2025 年 9 月 11 日（周四）15:00-17:00。 出席本次活动的有公司副董事长、总经理 WANG HONGQI（王洪琦）先生， 独立董事侯欣一先生和罗明生先生，副总经理、财务总监兼董事会秘书陈轶青先 生（如有特殊情况，出席人员会有调整）。届时公司将在线就公司 2025 年半年度 业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 中源协和细胞基因工程股份有限公司 二○二五年九月五日 1 中源协和细胞基因工程股份有限公司 关于参加 2025 年天津辖区上市公司投资者网上集体 接待日暨半年报业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流 ...

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

格隆汇8月27日丨中源协和(600645.SH)发布2025年半年度报告，报告期实现营业收入7.16亿元，同比下 降10.71%；归属上市公司股东的净利润5777.05万元，同比下降32.18%；扣除非经常性损益后的归属于 上市公司股东的净利润5389.17万元，同比下降35.82%；基本每股收益0.13元。 ...

中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二十一 次董事会会议于 2025 年 8 月 27 日以通讯表决方式召开。会议通知和会议资料 已于 2025 年 8 月 16 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定， 表决有效。经出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度报 告》全文及摘要； 证券代码：600645 证券简称：中源协和 公告编号：2025-033 中源协和细胞基因工程股份有限公司 十一届二十一次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案经公司第十一届董事会审计委员会 2025 年第五次会议审议通过。 《公司 2025 年半年度报告》全文及摘要详见上海证券交易所网站 www.sse.com.cn。 2、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度募 集资金存放与实际使用情况的专 ...

[Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This chapter defines key terms, regulatory bodies, company entities, biotechnology terms, and reporting periods for clear understanding of the report content - The report defines key entities and professional terms such as **China Securities Regulatory Commission (CSRC)**, **the Company**, **Jiadao Success**, **Deyuan Health**, **OriGene Technologies, Inc.**, **In Vitro Diagnostics (IVD)**, **Mesenchymal Stem Cells (MSC)**, **induced Pluripotent Stem Cells (iPSC)**, **National Medical Products Administration (NMPA)**, **Center for Drug Evaluation (CDE)**, and **Food and Drug Administration (FDA)**[15](index=15&type=chunk) [Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and key financial performance indicators [Company Information](index=4&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section presents the company's fundamental registration details, including its Chinese name, abbreviation, foreign name, and legal representative Company Basic Information | Metric | Content | | :--- | :--- | | Chinese Name | 中源协和细胞基因工程股份有限公司 | | Chinese Abbreviation | 中源协和 | | Foreign Name | VCANBIO CELL & GENE ENGINEERING CORP., LTD | | Legal Representative | WANG HONGQI（王洪琦） | [Contacts and Contact Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, faxes, and email addresses Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | 陈轶青 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | | Securities Affairs Representative | 张奋 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | [Brief Introduction to Changes in Basic Information](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5%E5%8F%98%E6%9B%B4%E7%AE%80%E4%BB%8B) This section outlines the company's current registered and office addresses, noting that historical changes are available in company announcements - The company's registered address is Floor 2, Building A, No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin, and its office address is No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[17](index=17&type=chunk) [Brief Introduction to Changes in Information Disclosure and Document Custody Locations](index=5&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) This section specifies the company's designated newspapers for information disclosure, the website for report publication, and the location for report availability - The company designates "China Securities Journal", "Shanghai Securities News", and "Securities Times" as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[18](index=18&type=chunk) [Overview of Company Shares](index=5&type=section&id=%E4%BA%94%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E7%A5%A8%E7%AE%80%E5%86%B5) This section provides a brief overview of the company's A-share stock, including its listing exchange, abbreviation, and code Company Stock Overview | Share Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A股 | 上海证券交易所 | 中源协和 | 600645 | [Company's Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's key accounting data and financial indicators for the current and prior periods, explaining the reasons for profit decline Key Accounting Data (Unit: yuan) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 716,369,723.52 | 802,285,328.09 | -10.71 | | Total Profit | 74,744,079.80 | 114,140,321.07 | -34.52 | | Net Profit Attributable to Shareholders | 57,770,452.54 | 85,185,087.67 | -32.18 | | Net Cash Flow from Operating Activities | 123,036,717.91 | 98,635,675.90 | 24.74 | Key Financial Indicators (Unit: yuan/share) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Basic EPS | 0.13 | 0.18 | -27.78 | | Diluted EPS | 0.13 | 0.18 | -27.78 | | Basic EPS after Non-recurring Gain/Loss | 0.12 | 0.18 | -33.33 | | Weighted Avg. ROE (%) | 1.59 | 2.32 | 减少0.73个百分点 | - The company's total profit, net profit attributable to shareholders, and net profit attributable to shareholders after non-recurring gain/loss decreased from the prior period, primarily due to a decline in reagent segment revenue and a year-on-year decrease in net profit[23](index=23&type=chunk) [Non-recurring Gain/Loss Items and Amounts](index=6&type=section&id=%E4%B9%9D%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) This section details the non-recurring gain/loss items and their amounts for the reporting period, totaling **3.88 million yuan** Non-recurring Gain/Loss Items and Amounts (Unit: yuan) | Non-recurring Gain/Loss Item | Amount | | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -332,722.36 | | Government Grants Recognized in Current P&L | 1,163,733.71 | | Fair Value Change G/L & Disposal G/L from Fin. Assets/Liabilities | 5,000,290.13 | | Reversal of Impairment for Receivables Individually Assessed | 351,418.58 | | Other Non-operating Income & Expenses | -223,827.70 | | Other Non-recurring G/L Items | -1,543,812.26 | | Less: Income Tax Impact | 370,288.98 | | Minority Interest Impact (After Tax) | 166,023.23 | | **Total** | **

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...